Cannabigerol - Another promising cannabinoid?

    October 04, 2022 2 min read

    Cannabigerol - Another promising cannabinoid?

    Cannabigerol (CBG), in its decarboxylated form, is the precursor molecule for the most abundant phytocannabinoids. Presumably because of this, and because of recent promise in medical applications for CBD, research and commercial attention is beginning to turn to CBG.Pharmacological profiling is still in its infancy; too little is known about the pharmacodynamics of cannabigerol for its release into an unregulated retail environment yet. But CBG is known to exhibit affinity and activity characteristics between Δ9-THC and CBD at the cannabinoid receptors, and it appears to have unique interactions withα-2 adrenoceptors and 5-hydroxytryptamine (5-HT1A). Preclinical data suggest that CBG could have therapeutic benefit in neurodegenerative disorders and inflammatory bowel disease, and may have antibacterial properties as well.Clinical trials are underway in psychiatry, pain, and addiction. CBG is known as well at this point to be a safe appetite stimulant in chemotherapy, and as an agent that reduces in vitro signs of pathology in colitis and colorectal cancer. 

    CBG demonstrates action on the PPAR family of receptors and improves insulin sensitivity and adipogenesis, and could for this reason have an eventual role to play in the treatment of metabolic disease. It also displays antihypertensive properties atα-2 receptors. These together could be of help to patients with diabetes, who frequently have hypertension, hyperlipidemia, and insulin resistance from glucose dysregulation and vascular endothelial dysfunction. 

    CBG, through the PPAR receptors, also appears to be neuroprotective. This, combined with data from other sources reporting reduction in cognitive decline in patients with neurodegenerative disease with the addition ofα-2 agonists, suggest that CBG may help in these populations too. 

    CBG may even have a role as concomitant therapy in disorders of the executive function, like schizophrenia and ADHD. Two currentα-2 agonists, clonidine and guanfacine, are in use now for theirα-2-mediated action in the prefrontal cortex. Clonidine is strongly antihypertensive, and CBG is not. Guanfacine is an adjunct therapy with stimulants in ADHD because of itsα-2A receptor subtype specificity. It will be known in time whether CBG shares this specificity. 


    PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, including CBG, please contact Damian Peters at 310-666-4869, or email

    The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.